Table 1. Summary of the primary endpoints i) plasma and tissue CoQ10 levels, and ii) plasma levels of specific biomarkers of ischemia-reperfusion damage (Troponin I and CK-MB).

Variable	QH (n=24)	Placebo (n=22)	P value
Plasma CoQ10 (nmol/mmol chol)
Phase 1	110.34 ± 11.75	115.85 ± 6.92	0.990
Phase 2	946.81 ± 149.63	120.31 ± 8.28	<0.001
Phase 3	789.58 ± 123.53	112.64 ± 7.48	<0.001
Phase 4	491.58 ± 90.42	94.67 ± 7.89	0.001
Plasma oxidized CoQ10 (%)
Phase 1	11 ± 1	11 ± 1	0.764
Phase 2	8 ± 2	14 ± 1	0.012
Phase 3	16 ± 2	25 ± 3	0.015
Phase 4	15 ± 2	17 ± 1	0.312
Cardiac CoQ10 content (μg/mg tissue)	0.047 ± 0.004	0.047 ± 0.003	0.973
Heart oxidized CoQ10 (%)	67 ± 2	70 ± 2	0.339
Troponin I (ng/dL)
Phase 1	0.02 (0.01 – 0.03)	0.06 (0.03 – 0.16)	0.098
Phase 2	2.67 (1.90 – 3.75)	2.92 (2.10 – 4.06)	0.992
Phase 3	1.90 (1.47 – 2.48)	4.03 (2.45 – 6.63)	0.007
Phase 4	0.29 (0.14 – 0.63)	0.49 (0.23 – 1.02)	0.783
CK-MB (ng/mL)
Phase 1	1.35 ± 0.14	2.42 ± 0.58	0.343
Phase 2	30.10 ± 7.32	31.21 ± 4.56	0.999
Phase 3	18.34 ± 2.47	32.93 ± 11.28	0.195
Phase 4	2.53 ± 0.52	5.86 ± 1.00	0.023